Virtual screening reveals allosteric inhibitors of the Toxoplasma gondii thymidylate synthase-dihydrofolate reductase.

Abstract

The parasite Toxoplasma gondii can lead to toxoplasmosis in those who are immunocompromised. To combat the infection, the enzyme responsible for nucleotide synthesis thymidylate synthase-dihydrofolate reductase (TS-DHFR) is a suitable drug target. We have used virtual screening to determine novel allosteric inhibitors at the interface between the two TS domains. Selected compounds from virtual screening inhibited TS activity. Thus, these results show that allosteric inhibition by small drug-like molecules can occur in T. gondii TS-DHFR and pave the way for new and potent species-specific inhibitors.

• Authors: Hitesh Sharma, Mark J Landau, Todd J Sullivan, Vidya P Kumar, Markus K Dahlgren, William L Jorgensen, Karen S Anderson
• Journal: Bioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 24 Issue 4 Pg. 1232-5 (Feb 15 2014) ISSN: 1464-3405 [Electronic] England
• PMID: 24440298 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2014 Elsevier Ltd. All rights reserved.

Chemical References

• Enzyme Inhibitors
• Multienzyme Complexes
• thymidylate synthase-dihydrofolate reductase
• Tetrahydrofolate Dehydrogenase
• Thymidylate Synthase

Topics

• Allosteric Regulation (drug effects)
• Dose-Response Relationship, Drug
• Drug Evaluation, Preclinical
• Enzyme Inhibitors (chemical synthesis, chemistry, pharmacology)
• Models, Molecular
• Molecular Structure
• Multienzyme Complexes (antagonists & inhibitors, metabolism)
• Structure-Activity Relationship
• Tetrahydrofolate Dehydrogenase (metabolism)
• Thymidylate Synthase (antagonists & inhibitors, metabolism)
• Toxoplasma (enzymology)